Related Experiment Video
Updated: May 26, 2026
04:42
Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
Uncoupling the dopamine D1-D2 receptor complex: a novel target for antidepressant treatment
1Department of Neuroscience, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Clinical Pharmacology and Therapeutics
|December 30, 2011
Summary
Major depressive disorder (MDD) is a disabling illness. Targeting dopamine receptors, specifically the interaction between dopamine D1 and D2, shows promise as a novel antidepressant strategy for treatment-resistant cases.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Major depressive disorder (MDD) is a leading cause of global disability.
- Existing antidepressants primarily target serotonin and norepinephrine systems.
- Treatment-resistant depression has limited therapeutic options.
Purpose of the Study:
- To explore the role of the dopamine system in mood regulation.
- To investigate the potential of dopamine receptor interactions as a novel antidepressant target.
Main Methods:
- Review of recent findings on dopamine's role in depression.
- Analysis of the interaction between dopamine D1 and D2 receptors.
Main Results:
- The dopamine neurotransmitter system modulates mood and depressive symptoms.
- A specific interaction between dopamine D1 and D2 receptors has been identified.
Conclusions:
- The dopamine D1-D2 receptor interaction represents a promising novel target for antidepressant development.
- This pathway offers a potential new avenue for treating depression, especially treatment-resistant forms.
More Related Videos
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...